Planned sale

Oruka Therapeutics (ORKA): Officer filed to sell ~$1.61M

JOANA GONCALVES, Officer at Oruka Therapeutics, filed to sell ~$1.61M of Oruka Therapeutics shares.

~$1.61M
planned to sell · 21K shares, around Oct 15, 2026
Planned for
Oct 15, 2026
Notice filed
Oct 15, 2026

What stands out in this filing

  • The planned sale is 0.03% of the company's shares outstanding, as stated on the notice.
  • How the shares were acquired, per the notice: Exercise of Stock Options.
  • The notice says the shares were received as pay (stock awards or options).
  • Broker named on the notice: Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Remarks on the notice: The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
  • A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026.”
  2. Oct 1, 2026Insider · 1 personInsiders: 3 sales (~$2.1M)
  3. Oct 12, 2026Insider · 1 personInsiders: 4 sales (~$806K)
  4. Oct 15, 2026Insider · 1 personInsiders: 5 sales (~$524K)

What came next

  1. Oct 20, 2026Insider · 1 personInsiders: 5 sales (~$707K)
  2. Nov 2, 2026Insider · 1 personInsiders: 5 sales (~$2.4M)
  3. Nov 12, 2026Insider · 2 peopleInsiders: 12 sales (~$2.9M)
  4. Nov 16, 20265% stakeRTW Investments, LP reported a passive stake (13G) of 4.7%
  5. Nov 16, 20265% stakeT. Rowe Price Investment Management, Inc. reported a passive stake (13G) of 6.6%
  6. Nov 16, 2026Insider · 1 personInsiders: 6 sales (~$707K)
  7. Nov 20, 2026Insider · 1 personInsiders: 4 sales (~$854K)
View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Oruka Therapeutics

For Oruka Therapeutics, OQRO holds 45 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ORKA page.

How this filing works

Explore the data

Common questions

Which Oruka Therapeutics (ORKA) insider traded, and how much?

JOANA GONCALVES, Officer at Oruka Therapeutics, filed to sell ~$1.61M of Oruka Therapeutics shares. 21K shares, Form 144 notice of a planned sale.

When did it happen, and when was it made public?

Planned for: Oct 15, 2026. Notice filed: Oct 15, 2026.

What stands out in this filing?

The planned sale is 0.03% of the company's shares outstanding, as stated on the notice. How the shares were acquired, per the notice: Exercise of Stock Options. The notice says the shares were received as pay (stock awards or options).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Oruka Therapeutics recently?

For Oruka Therapeutics, OQRO holds 45 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ORKA page.

Does this mean ORKA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Oruka Therapeutics

Everything OQRO holds on this company is on its ORKA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data